Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial

[1]  G. Mancia,et al.  Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension , 2022, Journal of hypertension.

[2]  G. M. Allan,et al.  Bedtime versus morning use of antihypertensives for cardiovascular risk reduction (BedMed): protocol for a prospective, randomised, open-label, blinded end-point pragmatic trial , 2022, BMJ Open.

[3]  T. MacDonald,et al.  A systematic review of methods used to conduct decentralised clinical trials , 2021, British journal of clinical pharmacology.

[4]  T. MacDonald,et al.  Factors influencing participation and long-term commitment to self-monitoring of blood pressure in a large remote clinical trial: The treatment in morning versus evening (TIME) study , 2021, Journal of Human Hypertension.

[5]  M. Smolensky,et al.  Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications: Controversies in Hypertension-Pro Side of the Argument. , 2021, HYPERTENSION.

[6]  J. Hogenesch,et al.  Lowering Nighttime Blood Pressure With Bedtime Dosing of Antihypertensive Medications , 2021, Hypertension.

[7]  S. Oparil,et al.  Missing Verification of Source Data in Hypertension Research , 2021, Hypertension.

[8]  R. Collins,et al.  Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis , 2021, The Lancet.

[9]  T. MacDonald,et al.  Factors influencing home blood pressure monitor ownership in a large clinical trial , 2021, Journal of Human Hypertension.

[10]  T. MacDonald,et al.  Home blood pressure monitors owned by participants in a large decentralised clinical trial in hypertension: the Treatment In Morning versus Evening (TIME) study , 2021, Journal of Human Hypertension.

[11]  K. Rahimi,et al.  Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK , 2021, Open Heart.

[12]  C. Reid,et al.  The effect of taking blood pressure lowering medication at night on cardiovascular disease risk. A systematic review , 2021, Journal of Human Hypertension.

[13]  T. Cameron Waller,et al.  Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial , 2020, The Lancet.

[14]  Dan J Stein,et al.  Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[15]  L. A. Phillips,et al.  Time-of-Day Differences in Treatment-Related Habit Strength and Adherence , 2020, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[16]  R. Hermida,et al.  Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. , 2019, European heart journal.

[17]  D. Thompson,et al.  Randomized Crossover Trial of the Impact of Morning or Evening Dosing of Antihypertensive Agents on 24-Hour Ambulatory Blood Pressure: The HARMONY Trial , 2018, Hypertension.

[18]  T. MacDonald,et al.  Protocol for assessment of sleep quality and duration in the Treatment In Morning versus Evening (TIME) study: a randomised controlled trial using online patient-reported outcome measures , 2018, BMJ Open.

[19]  T. MacDonald,et al.  The Treatment In Morning versus Evening (TIME) study: analysis of recruitment, follow-up and retention rates post-recruitment , 2017, Trials.

[20]  Blair H. Smith,et al.  Cohort profile: the Scottish Research register SHARE. A register of people interested in research participation linked to NHS data sets , 2017, BMJ Open.

[21]  J. McMurray,et al.  Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) , 2016, European heart journal.

[22]  K. Kario,et al.  Prognostic Effect of the Nocturnal Blood Pressure Fall in Hypertensive Patients: The Ambulatory Blood Pressure Collaboration in Patients With Hypertension (ABC-H) Meta-Analysis. , 2016, Hypertension.

[23]  D. Webb,et al.  Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study , 2016, BMJ Open.

[24]  H. Steffen,et al.  Circadian Variation in Arterial Blood Pressure and Glaucomatous Optic Neuropathy--A Systematic Review and Meta-Analysis. , 2015, American journal of hypertension.

[25]  G. Nagel,et al.  Blood pressure and falls in community-dwelling people aged 60 years and older in the VHM&PP cohort , 2013, BMC Geriatrics.

[26]  K. Kario.  Morning Surge in Blood Pressure and Cardiovascular Risk: Evidence and Perspectives , 2010, Hypertension.

[27]  R. Hermida,et al.  INFLUENCE OF CIRCADIAN TIME OF HYPERTENSION TREATMENT ON CARDIOVASCULAR RISK: RESULTS OF THE MAPEC STUDY , 2010, Chronobiology international.

[28]  J. Staessen,et al.  Night–day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension , 2009, Journal of Human Hypertension.

[29]  Kerina H. Jones,et al.  The SAIL databank: linking multiple health and social care datasets , 2009, BMC Medical Informatics Decis. Mak..

[30]  John Urquhart,et al.  Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories , 2008, BMJ : British Medical Journal.

[31]  R. Hermida,et al.  Treatment of non-dipper hypertension with bedtime administration of valsartan , 2005, Journal of hypertension.

[32]  J E Schwartz,et al.  Stroke Prognosis and Abnormal Nocturnal Blood Pressure Falls in Older Hypertensives , 2001, Hypertension.